Cambrian Biopharma

Cambrian pioneered a structurally clever answer to the core problem of aging drug discovery — that any single asset is a coin flip — by running a distributed "PipeCo" model akin to Roivant or atai: it builds and finances a portfolio of affiliate companies, each attacking a distinct biological driver of aging, spreading risk across many shots on goal while sharing operational infrastructure, scientific advisory, and capital-raising muscle. Co-founded by CEO James Peyer and chairman Christian Angermayer, Cambrian closed an oversubscribed $100M Series C in October 2021 (co-led by Anthos Capital and the SALT Fund, with Apeiron, Future Ventures, and Moore Capital), having raised over $200M across its programs. The portfolio has produced tangible clinical progress: affiliate Amplifier Therapeutics' ATX-304, a peripherally restricted oral AMPK and mitochondrial activator, completed Phase 1 showing metabolic activation in humans and is advancing toward Phase 2 in obesity and cardiometabolic disease, with combination data alongside semaglutide presented at ENDO 2025 — positioning it in the white-hot GLP-1-adjacent metabolic space. Other affiliates (Tornado's next-gen mTOR inhibitors, Telos's senescence-resistant cell therapies) diversify across aging hallmarks. The structure lets Cambrian spin winners toward partnerships or IPOs while capping downside on losers.